Assessing the Length of Hospital Stay and Economic Outlay for Therapy in Chronic Kidney Disease Patients in a Tertiary Care Hospital
,
Abstract
Background: To assess the LOS and costs for hospitalized CKD patients, to compare the pharmacoeconomic-related direct medical and non-medical costs among pre-dialysis and dialysis patients, and to determine the impact of CKD with other comorbidities on hospital LOS and cost. Methods: An observational study was conducted on 160 patients admitted to the Nephrology Department. From the collected data, the direct and indirect costs of the treatment were analyzed using a standard questionnaire. Results: Dialysis was significantly correlated with total cost and total indirect cost rather than total direct cost. The statistical analysis showed that comorbidities and LOS were not significantly correlated, which shows that CKD alone is responsible for increased LOS. Both LOS and cost were significantly correlated (p-value 0.00). The stage of CKD and the type of treatment being used are the main determinants of LOS. Direct medical, direct non-medical, and total direct costs were significantly related to comorbidities (p-value 0.004, 0.005, and 0.058, respectively). Conclusion: The study revealed that dialysis was significantly correlated with total cost and total indirect cost. Dialysis treatments, hospital stays, and other CKD-related requirements necessitated many time-consuming visits and procedures. According to the study's analysis of the data, there is no statistically significant relationship between comorbidities and LOS. This demonstrates that the lengthening of stays is solely attributable to CKDAnitha, N., Fatima, T. T., & Mrudula, G. (2017). Pharmacoeconomic evaluation in end-stage renal disease patients. Journal of Pharmaceutical Research, 16(1), 14. http://dx.doi.org/10.18579/jpcrkc/2017/16/1/112468
Bajwah, S., Oluyase, A. O., Yi, D., Gao, W., Evans, C. J., Grande, G., et al. (2020). The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers. Cochrane Database of Systematic Reviews, 9(9). https://pubmed.ncbi.nlm.nih.gov/32996586/ http://dx.doi.org/10.1002/14651858.cd012780.pub2
Balasubramanian, G., McKitty, K., & Fan, S. L. S. (2011). Comparing automated peritoneal dialysis with continuous ambulatory peritoneal dialysis: survival and quality of life differences? Nephrology Dialysis Transplantation, 26(5), 1702-1708. https://pubmed.ncbi.nlm.nih.gov/20921296/ http://dx.doi.org/10.1093/ndt/gfq607
Bombardier, C., & Maetzel, A. (1999). Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Annals of the Rheumatic Diseases, 58(suppl 1), I82-I85. https://ard.bmj.com/content/58/suppl_1/I82 http://dx.doi.org/10.1136/ard.58.2008.i82
Chan, W., Johnson, K. W., Navaratnam, P., & Friedman, H. (2014). Impact of Kidney Disease Severity on Length of Stay, Hospital Readmissions, Mortality, and Costs Associated with Patients Hospitalized with Heart Failure (HF). Heart & Lung, 43(4), 383-384. http://www.heartandlung.org/article/S0147956314002039/fulltext http://dx.doi.org/10.1016/j.hrtlng.2014.06.015
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic Kidney Disease Diagnosis and Management: A Review. JAMA, 322(13), 1294-1304. https://jamanetwork.com/journals/jama/fullarticle/2752067 http://dx.doi.org/10.1001/jama.2019.14745
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., et al. (2007). Prevalence of Chronic Kidney Disease in the United States. JAMA, 298(17), 2038-2047. https://jamanetwork.com/journals/jama/fullarticle/209357 http://dx.doi.org/10.1001/jama.298.17.2038
Engels, N., De Graav, G. N., Van Der Nat, P., Van Den Dorpel, M., Stiggelbout, A. M., & Bos, W. J. (2022). Shared decision-making in advanced kidney disease: A scoping review. BMJ Open, 12(9). http://dx.doi.org/10.1136/bmjopen-2021-055248
Fathima, S., Mateti, U., Philip, M., & Kamath, J. (2018). Pharmacoeconomic evaluation of hemodialysis patients: A study of cost of illness. Journal of Integrative Nephrology and Andrology, 5(2), 54. http://dx.doi.org/10.4103/jina.jina_4_18
Finkelstein, F. O., Schiller, B., Daoui, R., Gehr, T. W., Kraus, M. A., Lea, J., et al. (2012). At-home short daily hemodialysis improves the long-term health-related quality of life. Kidney International, 82(5), 561-569. https://pubmed.ncbi.nlm.nih.gov/22622497/ http://dx.doi.org/10.1038/ki.2012.168
Freeman, C., Giles, L., Field, P., Sörstadius, E., & van Haalen, H. (2019). Humanistic burden and economic impact of chronic kidney disease: a systematic literature review. F1000Research, 8, 2142. https://europepmc.org/article/ppr/ppr106884 http://dx.doi.org/10.12688/f1000research.21374.1
Garg, A. X., Suri, R. S., Eggers, P., Finkelstein, F. O., Greene, T., Kimmel, P. L., et al. (2017). Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis. Kidney International, 91(3), 746-754. https://pubmed.ncbi.nlm.nih.gov/28094031/ http://dx.doi.org/10.1016/j.kint.2016.10.033
Ghelichi-Ghojogh, M., Fararouei, M., Seif, M., & Pakfetrat, M. (2022). Chronic kidney disease and its health-related factors: a case-control study. BMC Nephrology, 23(1), 1-7. https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02655-w http://dx.doi.org/10.1186/s12882-021-02655-w
Grams, M. E., Chow, E. K. H., Segev, D. L., & Coresh, J. (2013). Lifetime incidence of CKD stages 3-5 in the United States. American Journal of Kidney Diseases, 62(2), 245-252. https://pubmed.ncbi.nlm.nih.gov/23566637/ http://dx.doi.org/10.1053/j.ajkd.2013.03.009
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O’Callaghan, C. A., Lasserson, D. S., et al. (2016). Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One, 11(7), e0158765. https://pmc/articles/PMC4934905/ http://dx.doi.org/10.1371/journal.pone.0158765
Mahajan, C., Tiwari, V., Divyaveer, S. S., Patil, M. R., Banerjee, A., Bagur, V., et al. (2020). Spectrum of renal biopsies; a three-year data from a tertiary care centre of eastern India. Journal of Nephropharmacology, 9(2), e20-e20. https://jnephropharmacology.com/Article/npj-5304 http://dx.doi.org/10.34172/npj.2020.20
Mateti, U. V., Nagappa, A. N., Vooradi, S., Madzaric, M., Mareddy, A. S., Attur, R. P., et al. (2015). Pharmacoeconomic evaluation of hospitalised pre-dialysis and dialysis patients: A comparative study. Australasian Medical Journal, 8(4), 132. https://pmc/articles/PMC4422953/ http://dx.doi.org/10.4066/amj.2015.2329
Mazairac, A. H. A., de Wit, G. A., Grooteman, M. P. C., Penne, E. L., van der Weerd, N. C., den Hoedt, C. H., et al. (2013). Effect of Hemodiafiltration on Quality of Life over Time. Clinical Journal of the American Society of Nephrology, 8(1), 82. https://pmc/articles/PMC3531648/ http://dx.doi.org/10.2215/cjn.00010112
Mills, K. T., Xu, Y., Zhang, W., Bundy, J. D., Chen, C. S., Kelly, T. N., et al. (2015). A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney International, 88(5), 950-957. http://dx.doi.org/10.1038/ki.2015.230
Senanayake, S., Graves, N., Healy, H., Baboolal, K., & Kularatna, S. (2020). Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review. Cost Effectiveness Research and Allocation, 18(1). https://pubmed.ncbi.nlm.nih.gov/32477010/ http://dx.doi.org/10.1186/s12962-020-00213-z
Stevens, P. E., & Levin, A. (2013). Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of Internal Medicine, 158(11), 825-830. https://doi.org/10.7326/0003-4819-158-11-201306040-00005
Sugrue, D. M., Ward, T., Rai, S., McEwan, P., & van Haalen, H. G. M. (2019). Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. In PharmacoEconomics (Vol. 37, pp. 1451–1468). Adis. http://dx.doi.org/10.1007/s40273-019-00835-z
Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharmaceutical Practice (Granada), 19(1), 1-10. http://dx.doi.org/10.18549/pharmpract.2021.1.2302
Wang, Z., Do Carmo, J. M., Aberdein, N., Zhou, X., Williams, J. M., Da Silva, A. A., et al. (2017). Synergistic Interaction of Hypertension and Diabetes in Promoting Kidney Injury and the Role of Endoplasmic Reticulum Stress. Hypertension, 69(5), 879-891. http://dx.doi.org/10.1161/hypertensionaha.116.08560
Y, S. S., Esther, C., Sultana, S. S., M, M., T, D. K., & G, K. (2020). Pharmacoeconomic evaluation of chronic kidney disease patients: a study on cost of illness. International Journal of Pharmaceutical Research and Life Sciences, 8(2), 82-88. https://scienztech.org/index.php/ijprls/article/view/1294 http://dx.doi.org/10.26452/ijprls.v8i2.1294
Yang, C., Long, J., Shi, Y., Zhou, Z., Wang, J., Zhao, M. H., et al. (2022). Healthcare resource utilisation for chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study. BMJ Open, 12(1), e051888. https://bmjopen.bmj.com/content/12/1/e051888 http://dx.doi.org/10.1136/bmjopen-2021-051888
Yong, D. S. P., Kwok, A. O. L., Wong, D. M. L., Suen, M. H. P., Chen, W. T., & Tse, D. M. W. (2009). Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliative Medicine, 23(2), 111-119. https://doi.org/10.1177/0269216308101099
Zahmatkesh, M., & Tamadon, M. R. (2018). World kidney day 2018; chronic kidney disease in women. In Journal of Nephropathology (Vol. 7, pp. 4-6). Society of Diabetic Nephropathy Prevention. http://dx.doi.org/10.15171/jnp.2018.02
Zeba, Z., Fatema, K., Sumit, A. F., Zinnat, R., & Ali, L. (2020). Early screening of chronic kidney disease patients among the asymptomatic adult population in Bangladesh. Journal of Preventive Epidemiology, 5(1), e10-e10. http://dx.doi.org/10.34172/jpe.2020.10
| Files | ||
| Issue | Vol 10 No 1 (2024) | |
| Section | Original Article(s) | |
| Keywords | ||
| Chronic Kidney Disease Dialysis Length of Stay Cost Comorbidities | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
